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Circulating MicroRNAs Implicate Multiple Atherogenic 
Abnormalities in the Long-Term Cardiovascular Sequelae of 
Preeclampsia
Natalie Dayan,1,2,* Kenny Schlosser,3,* Duncan J. Stewart,3,4 Christian Delles,5 Amanpreet Kaur,2 and 
Louise Pilote1,2
BACKGROUND
Women who have had preeclampsia (PE) are at increased risk for pre-
mature cardiovascular disease (CVD). The underlying pathophysiology 
of this risk remains unclear, but potentially involves subclinical vascular 
damage or dysfunction. Alterations in the levels of circulating microR-
NAs may be implicated, as they are known to play pervasive roles in vas-
cular biology. We investigated whether levels of circulating microRNAs 
are altered between women with premature acute coronary syndrome 
(ACS), with and without a history of PE.
METHODS
Women with premature ACS (age ≤ 55 years) were categorized based 
on a prior history of PE or normotensive pregnancy. Relative plasma 
levels of 372 microRNAs were initially assessed by polymerase chain 
reaction array in a subset of subjects (n  =  12–13/group) matched 
for age, chronic hypertension, dyslipidemia, and smoking status. 
Candidate microRNAs were then validated in a larger cohort of ACS 
patients (n = 176).
RESULTS
MicroRNAs previously linked to angiogenesis (miR-126-3p), inflamma-
tion (miR-146a-5p), and cholesterol metabolism (miR-122-5p) were 
significantly decreased in women with prior PE compared to women 
with prior normotensive pregnancy (P = 0.002, 0.017, and 0.009, respec-
tively), even after adjustment for chronic hypertension.
CONCLUSIONS
Circulating levels of miR-126-3p, -146a-5p, and -122-5p were signifi-
cantly decreased in women with premature ACS who reported prior 
PE compared to those with prior normotensive pregnancy. These data 
provide novel insight into potential pathways that may contribute to 
the increased risk of CVD following PE.
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Preeclampsia (PE) is a multisystem disorder of pregnancy 
characterized by high blood pressure and either proteinuria 
or other adverse conditions, and is associated with widespread 
maternal endothelial dysfunction.1 It complicates 2–8% of all 
pregnancies globally, and therefore imposes a significant bur-
den on the cardiovascular health of over 300 million women 
worldwide.2 Although PE typically resolves after delivery of 
the placenta, exposed women have a 2-fold higher risk of 
premature cardiovascular disease (CVD) and cardiovascular 
mortality later in life, with onset 10–15 years after delivery.2,3 
However, the molecular determinants underlying this elevated 
risk remain poorly defined. Increased rates of hypertension 
and metabolic syndrome have been noted after deliveries com-
plicated by PE.4 Furthermore, markers of subclinical athero-
sclerosis including pulse wave velocity, augmentation index, 
and carotid intima-media thickness have been demonstrated 
to be abnormal in women with past PE compared to women 
with past normotensive pregnancy.5 However, assessment of 
protein biomarkers involved in endothelial cell function and 
angiogenic pathways linking PE with future CVD have not 
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revealed similar insights.5,6 Moreover, to our knowledge no 
studies have assessed markers of vascular impairment after 
PE in the context of an acute ischemic event.
MicroRNAs (miRNAs) are small (~22 nucleotide) non-
coding RNAs that regulate gene expression at the post-tran-
scriptional level, and have been shown to play important 
and pervasive roles in vascular biology.7,8 Perturbations in 
the levels of circulating extracellular miRNAs may poten-
tially reflect disease-specific mechanisms of tissue injury or 
transcriptional reprogramming in dysfunctional tissues, or 
contribute to intercellular communication.7 While previous 
studies have demonstrated the importance of miRNAs in 
cardiovascular health and disease,9 and acutely at the time of 
PE,10 their potential contribution to disease activity linking 
PE and future CVD has not yet been investigated. Thus, we 
sought to determine whether a history of PE was associated 
with alterations in circulating miRNA levels in plasma sam-
pled at the time of an acute ischemic event.
METHODS
We investigated a subset of women with premature acute 
coronary syndrome (ACS) identified from the GENESIS-
PRAXY study,11 a multicenter cohort of adults aged ≤ 
55  years who were hospitalized with a diagnosis of ACS 
between January 2009 and April 2013 from 24 centers across 
Canada, 1 in the United States and 1 in Switzerland. For 
the present study, we included all parous women with ACS 
(n = 30 with prior PE, and n = 146 with prior normoten-
sive pregnancy) with adequate plasma samples drawn at 
study entry (Table 1). All participating sites received ethics 
approval from their respective ethics review boards, and par-
ticipants provided informed written consent. The diagnosis 
of ACS was standard, based on the presence of characteristic 
symptoms plus at least one of: (i) significant electrocardio-
gram changes in ≥ 2 contiguous leads: transient ST-segment 
elevations of ≥ 1 mm, ST-segment depressions of ≥ 1 mm, 
new T-wave inversions of ≥ 1 mm, pseudonormalization of 
previously inverted T waves, new Q waves (one-third the 
height of the R wave or ≥ 0.04 seconds), new R > S wave in 
lead V1 (posterior myocardial infarction), new left bundle 
branch block; (ii) increase in cardiac enzymes levels: tropo-
nin I  or T, creatine kinase-MB value > 2 × upper limit of 
the hospital’s normal range or if not available, then total cre-
atine phosphokinase value > 2 × upper limit of the hospi-
tal’s normal range. Pregnancy data was collected by detailed 
self-reported questionnaires at study entry. Women were 
classified as prior PE if they reported either PE or high 
blood pressure in addition to proteinuria. Women who were 
unsure about past pregnancy complications were excluded. 
The time since last pregnancy was estimated using age of 
youngest biological child.
Venipuncture was performed on all consenting par-
ticipants within 24 hours of hospital admission for ACS. 
Archived plasma samples (stored at −80 °C) were previously 
prepared by centrifuging whole blood at 3,000  rpm for 10 
minutes at 4  °C. Poor quality specimens with evidence of 
hemolysis or possible RNA degradation were not included 
among the final cohort of 176 subjects. A 2-phase discovery 
and validation approach was used to identify candidate 
plasma miRNAs that were associated with prior PE at the 
time of ACS. Circulating extracellular miRNAs were meas-
ured according to previously published methods.12 Briefly, 
total RNA was extracted from 200 µl of EDTA plasma using 
the miRNeasy mini kit (Qiagen). A  fixed volume of RNA 
eluate was converted to cDNA with the miScript II RT kit 
(Qiagen), and quantified on a Biorad CFX384 PCR machine 
using miScript primers and polymerase chain reaction rea-
gents (Qiagen). MiRNA levels were calculated as relative 
expression units, 2-ΔCq, normalized to a cel-miR-39 spike-in 
control and loge transformed for statistical analysis.
The derivation cohort used for miRNA screening included 
12–13 ACS patients each with a history of PE or normoten-
sive pregnancy, matched on age, hypertension, smoking 
status, and dyslipidemia. No miRNAs passed a false dis-
covery rate correction for multiple comparisons at P < 0.05. 
Therefore, miRNA candidates were initially prioritized 
according to unadjusted P-values, and then a subset were 
selected for further validation in the entire patient cohort 
(n  =  176) based on the magnitude of difference between 
exposure groups and mean circulating level.
Baseline characteristics and circulating miRNA values 
were compared in women with and without a history of PE 
using t-test, chi-square, or Mann–Whitney rank sum tests 
as appropriate. Multivariate linear and logistic regression 
were performed to assess the association between candidate 
miRNAs modeled as dependent variables (continuous or 
dichotomized at mean circulating levels) with a history of 
PE or normotensive pregnancy adjusted for current hyper-
tension, with statistical significance at 2-sided alpha 0.05. 
Spearman correlation coefficients (ρ) were determined 
between circulating levels of target miRNAs and several pre-
viously reported biological markers,6 including total choles-
terol (mg/dl), low-density lipoprotein (mg/dl), high-denisity 
lipoprotein (mg/dl), standardized troponin, soluble fms-
like tyrosine kinase (sflt-1, pg/ml), Placental Growth Factor 
(PlGF, pg/ml), and soluble endoglin (pg/ml).
RESULTS
Women with prior PE were significantly younger at the 
time of ACS compared to women with prior normotensive 
pregnancy (46.1 ± 6.6 years vs. 49.5 ± 5.0 years, P = 0.002), 
and accordingly had been pregnant more recently (14.2 years 
vs. 20.2 years prior, P = 0.0005). Women with prior PE were 
also more likely to have a diagnosis of chronic hypertension 
(86.7% with prior PE vs. 37.7% with prior normotensive 
pregnancy, P < 0.0001); however, mean systolic blood pres-
sure at ACS presentation did not significantly differ between 
groups.
We screened 372 circulating miRNAs in the derivation co-
hort. A total of 16 miRNA candidates were identified, which 
showed differential levels (based on an unadjusted P < 0.05 
cutoff) between women with prior PE compared to those 
with prior normotensive pregnancy, including 10 miRNAs 
that were increased (1.3–2.0-fold change) and 6 miRNAs 
that were decreased (1.3–2.8-fold change) in PE. Of these 16 
miRNAs, we further prioritized 3 candidates (miR-122-5p, 
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Table 1. Baseline characteristics of participants selected for this study
Characteristics Normotensive, n = 146 Preeclampsia, n = 30 P value
Demographics
 Age, years, mean (SD) 49.5 (5.0) 46.1 (6.6) 0.0016
 Caucasian, n (%) 130 (89.0) 27 (90.0) 0.87
Clinical risk factors, n (%)
 Hypertension 55 (37.7) 26 (86.7) <0.0001
 Diabetes 27 (18.5) 7 (23.3) 0.54
 Dyslipidemia 72 (49.3) 20 (66.7) 0.08
 Obesity (BMI ≥ 30 kg/m2) 51 (35.7) 13 (44.8) 0.35
 History of CAD 31 (21.2) 11 (36.7) 0.07
 Current smoking 66 (45.2) 11 (36.7) 0.39
Pregnancy characteristics
 History of fetal loss, n (%) 17 (11.6) 7 (23.3) 0.09
 Years since pregnancy, mean (SD) 20.2 (7.5) 14.2 (8.4) 0.0003
 Gestational diabetes, n (%) 11 (7.5) 7 (23.3) 0.009
Type of ACS, n (%)
 STEMI 68 (46.6) 19 (63.3) 0.09
 Non-STEMI 61 (41.8) 11 (36.7) 0.60
 Unstable angina 17 (11.6) 0 (0.0) 0.05
Biomarkers, mean (SD)
 Total cholesterol (mmol/l) 4.6 (1.3) 4.4 (1.5) 0.62
 Low density lipoprotein (mmol/l) 2.7 (1.2) 2.5 (1.4) 0.54
 Standardized troponin (μg/l) 10.2 (20.2) 20.8 (50.8) 0.07
 Sflt-1 (pg/ml) 140.1 (200.0) 187.2 (265.2) 0.27
 PlGF (pg/ml) 31.5 (24.8) 27.1 (14.1) 0.35
 Soluble endoglin (pg/ml) 771.4 (311.1) 758.5 (244.0) 0.83
Abbreviations: ACS, acute coronary syndrome; BMI, body mass index; CAD, coronary artery disease; PlGF, placental growth factor; STEMI, 
ST-elevation myocardial infarction.
Figure 1. Plasma levels of miR-122-5p, miR-126-3p, and miR-146a-5p in a cohort of women with premature ACS, stratified according to a history of 
preeclampsia (n = 30) or normotensive pregnancy (n = 146).
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miR-146a-5p, and miR-126a-3p) that met predefined crite-
ria for assessment in the larger validation cohort. These miR-
NAs have potentially relevant biological functions, including 
hepatic lipid metabolism (miR-122-5p), angiogenesis (miR-
126-3p), and anti-inflammatory (miR-146a-5p), and all have 
been implicated in the atherogenic process.13
In the larger cohort (n = 176; n = 30 with prior PE) all 
3 miRNAs were significantly (P  <  0.05) downregulated in 
plasma of ACS patients with a history of prior PE vs. those 
with prior normotensive pregnancy (Figure 1). After adjust-
ment for chronic hypertension, miRNA-122-5p remained 
significantly inversely associated with a history of PE (odds 
ratio [OR] 0.66, 95% confidence interval [CI] 0.47–0.92), 
as were miR-126-3p (OR 0.48, 95% CI 0.29–0.78) and miR-
146a-5p (OR 0.57, 95% CI 0.35–0.91) when each of these 
miRNAs were dichotomized at their mean circulating level.
In a correlation analysis of log-transformed miRNAs and 
several other relevant biomarkers, miR-122-5p was nega-
tively correlated with total cholesterol (ρ = −0.21, P = 0.03) 
and standardized troponin (ρ  =  −0.25, P  =  0.007). miR-
126-3p was negatively correlated with standardized troponin 
(ρ = −0.19, P = 0.04), and positively correlated with Placental 
Growth Factor (ρ = 0.14, P = 0.05). miR-146a-5p was posi-
tively correlated with endoglin (ρ  =  0.21, P  =  0.006) and 
Placental Growth Factor (ρ = 0.25; P = 0.0007).
DISCUSSION
The aim of this present study was to explore whether 
miRNA patterns would distinguish women with prior PE 
from women with prior normotensive pregnancy at the time 
of ACS. We hypothesized that significant differences in cir-
culating miRNAs might discern potential cellular mecha-
nisms of premature ischemic heart disease in 2 groups of 
women based on their prior pregnancy history.
Our findings suggest that PE may promote subclinical 
perturbations in multiple atherogenic pathways that persist 
even after resolution of PE, which could predispose affected 
women to future CVD. A recent review on miRNAs impli-
cated in the pathogenesis of atherosclerosis identified these 
same candidate miRNAs as playing central roles.13 miR-126 
is highly expressed in endothelial cells14 and inhibits the 
expression of vascular cell adhesion molecule 1 (VCAM1). 
miR-126 also regulates endothelial proliferation after vas-
cular injury. Thus, down-regulation of miR-126 is associ-
ated with reduced endothelial proliferation, and promotes 
atherogenesis.13,14 MiR-146 has an important role in sup-
pressing endothelial activation and inflammatory pathway 
regulation by potentiating T-cell receptors.15 Decreased lev-
els of miR-146 can lead to unsuppressed inflammation and 
endothelial activation. miR-122 regulates fat and cholesterol 
metabolism, and genetic deletion of miR-122 in mice has 
been shown to increase lipid synthesis, inflammation, and 
fibrosis in the liver.13,16 Thus, alterations in these miRNAs 
may potentiate various steps of the atherogenic process in 
women who have had PE. We also found correlations be-
tween circulating levels of miRNAs and other biomarkers of 
angiogenesis, cardiac damage and lipid metabolism that may 
provide insights into the biological action of these miRNAs, 
but due to the complexity of miRNA effects on gene expres-
sion such exploratory data should be interpreted with cau-
tion. The potential interplay between perturbations in the 
circulating extracellular levels of these miRNAs and their 
epigenetic intracellular roles in women with a history of PE 
deserves further study.
Our data should be considered hypothesis-generating, 
since the observational nature of this study with retrospect-
ive ascertainment of pregnancy history precludes discus-
sion of any causal link between these altered circulating 
miRNAs, PE and ACS. Furthermore, the lack of a healthy 
comparison group limits our understanding of the impact of 
the ACS itself on circulating extracellular miRNAs. Future 
studies that compare miRNA profiles in healthy women with 
women who have ischemic heart disease and correlate with 
past pregnancy events will help to clarify this association. 
Nevertheless, this is the first study to implicate a potential 
role for dysregulated circulating miRNAs in the long-term 
cardiovascular sequelae of PE. We identify novel molecu-
lar targets that merit further investigation in independent 
patient cohorts, and interrogation in animal models, to help 
delineate whether these altered miRNAs are markers or 
mediators of underlying disease activity.
ACKNOWLEDGMENTS
The authors thank Ms Jasmine Poole and Ms Marisa 
Okano for technical assistance and Dr Hassan Behlouli for 
statistical support. This study was supported by the Canadian 
Vascular Network. C.D.  received grants from the British 
Heart Foundation (Centre of Research Excellence Award 
RE/13/5/30177) and the Chief Scientist Office (Scotland) 
(ETM/196).
DISCLOSURE
The authors declared no conflict of interest.
REFERENCES
 1. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian 
Hypertensive Disorders of Pregnancy Working Group. Diagnosis, eval-
uation, and management of the hypertensive disorders of pregnancy: 
an executive summary. J Obstet Gynaecol Can 2014; 36:416–441.
 2. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia 
and future cardiovascular risk among women: a review. J Am Coll 
Cardiol 2014; 63:1815–1822.
 3. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia 
and risk of cardiovascular disease and cancer later in life: a sys-
tematic review and meta-analysis. British Medical Journal 2007; 
335:974–985.
 4. Al-Nasiry S, Ghossein-Doha C, Polman SEJ, Lemmens S, Scholten RR, 
Heidema WM, Spaan JJ, Spaanderman ME. Metabolic syndrome after 
pregnancies complicated by pre-eclampsia or small for gestational age: 
a retrospective cohort. Br J Obset Gynaecol 2015; 122: 1818–1823.
 5. Grand’Maison S, Pilote L, Okano M, Landry T, Dayan N. Markers of 
vascular dysfunction after hypertensive disorders of pregnancy: a sys-
tematic review and meta-analysis. Hypertension 2016; 68:1447–1458.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajh/article-abstract/31/10/1093/5001828 by U
niversity of G
lasgow
 user on 26 N
ovem
ber 2018
American Journal of Hypertension 31(10) October 2018 1097
MiRNAs, Preeclampsia, and Cardiovascular Disease
 6. Grand’Maison S, Pilote L, Schlosser K, Stewart DJ, Okano M, Dayan 
N. Clinical features and outcomes of acute coronary syndrome in 
women with previous pregnancy complications. Can J Cardiol. 2017; 
33:1683–1692.
 7. Zampetaki A, Fashawe B, Mayr M. The therapeutic potential of micro-
RNAs in heart and vascular disease. Heart Metab 2014; 65:21–25.
 8. Murphy MS, Casselman RC, Tayade C, Smith GN. Differential expres-
sion of plasma microRNA in preeclamptic patients at delivery and 
1 year postpartum. Am J Obstet Gynecol 2015; 213:367.e1–367.e9.
 9. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular 
biology. Nature 2011; 469:336–342.
 10. Sheikh AM, Small HY, Currie G, Delles C. Systematic review of micro-
RNA expression in pre-eclampsia identifies a number of common path-
ways associated with the disease. PLoS One 2016; 11:e0160808.
 11. Pilote L, Karp I. GENESIS-PRAXY (GENdEr and Sex determInantS 
of cardiovascular disease: from bench to beyond-Premature Acute 
Coronary SYndrome). Am Heart J 2012; 163:741–746.e2.
 12. Schlosser K, White RJ, Stewart DJ. miR-26a linked to pulmonary hyper-
tension by global assessment of circulating extracellular microRNAs. 
Am J Respir Crit Care Med 2013; 188:1472–1475.
 13. Laffont B, Rayner KJ. MicroRNAs in the pathobiology and therapy of 
atherosclerosis. Can J Cardiol 2017; 33:313–324.
 14. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, 
Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR-126 
governs vascular integrity and angiogenesis. Dev Cell 2008; 15:261–271.
 15. Etzrodt M, Cortez-Retamozo V, Newton A, Zhao J, Ng A, Wildgruber 
M, Romero P, Wurdinger T, Xavier R, Geissmann F, Meylan E, 
Nahrendorf M, Swirski FK, Baltimore D, Weissleder R, Pittet MJ. 
Regulation of monocyte functional heterogeneity by miR-146a and 
Relb. Cell Rep 2012; 1:317–324.
 16. Wang L, Tang W, Yan S, Zhou L, Shen T, Huang X, Dou L, Wang M, 
Yu S, Li J. Efficient delivery of miR-122 to regulate cholesterol metabo-
lism using a non-covalent peptide-based strategy. Mol Med Rep 2013; 
8:1472–1478.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajh/article-abstract/31/10/1093/5001828 by U
niversity of G
lasgow
 user on 26 N
ovem
ber 2018
